Epitalon (일명 에피탈론)과 밀접한 관련이있는 짧은 펩티드 인 Livagen은 면역계, GI 트랙 및 간에 미치는 영향으로 알려져 있습니다. 펩티드 바이오 레게 글터로서, Livagen은 DNA 및 유전자 발현 패턴에 직접적인 영향을 미칩니다. 그 반면 노화 방지 특성은 Livagen의 GI 관 및 면역계에서 유전자를 활성화하는 능력과 나이에 따른 DNA 응축의 결과로 침묵하는 것으로 생각됩니다.

Amino Acid Sequence: Lys-Glu-Asp-Ala Molecular Formula: C₁₈시간₃₁N₅영형₉ Molecular Weight: 461.5 g/mol PubChem CID: 87919683 CAS No: 195875-84-4 (Deprecated: 402856-42-2) Alternative Names: SCHEMBL5967826 Source: PubChem

DNA is contained within the nucleus of eukaryotes, like humans, in a hierarchy of ever more condensed organization that takes the roughly 3 feet of DNA that is contained within a human cell and packages it to fit within the space of one hundredth of a millimeter. In other words, the packaging of DNA reduces its overall size by about 100,000 times. The double helix of DNA is wrapped around proteins, called histones, which themselves conglomerate to form chromatin structure, which further condenses to form chromosomes. This progressive organization of DNA serves several purposes including condensing the genetic material for replication and cell division, condensing the genetic material so that it fits within cells, and controlling expression of genes at a very high level. In other words, DNA organization is all about packaging the genetic material and about controlling access to specific genes[1]. The latter function of chromatin, controlling gene expression, Source: NIH : 국립보건원 Research in older adults suggests that Livagen activates a number of genes in the lymphocytes of older people by inducing the decondensation (unpacking) of chromatin. This results in the activation of genes that are otherwise silent in older adults including ribosomal genes responsible, indirectly, for robust protein production and enhanced cell activity[2]. This information suggests that Livagen has a direct effect on the DNA within lymphocytes, which are a primary cell of the immune system. Research looking that the end-points of Livagen, Epitalon, and Vilon administration in elderly individuals shows that Livagen has four different effects in lymphocytes including • activating synthetic processes by reactivating ribosomal genes, • unpacking chromatin, • altering gene expression, and • inducing decondensation. All of these effects lead to reactivation of chromatin that is silenced as we age[3]. Though long-term effects have not been studied, there is the belief among researchers that this resets lymphocytes to a more “youthful” state. Lymphocytes are a class of white blood cell that contains B cells and T cells. B cells produce antibodies  against foreign invaders while T cells destroy cells of the body that are either infected with an invading organism or have become cancerous. T cells also produce cytokines, which are chemical signals that coordinate immune responses and control inflammation in the body[4]. In other words, lymphocytes are among the most important cells of the immune system. Their decline in activity with age may be at least part of the explanation for why we become more susceptible to all varieties of disease and illness as we age. The ability to reset these cells to a more youthful state could help to ward off infection and cancer.

Livagen과 마음

Lymphocytes play an active role in cardiac health, so it was natural for researchers to wonder what effects Livagen might have on the heart. Research in patients with hypertrophic cardiomyopathy (HCM) suggests that dysregulation of chromatin structure in lymphocytes is a pathogenic feature in HCM and atherosclerosis that, if correct, may improve long-term outcomes[5]. Several studies suggest that release of genes via decondensation of chromatin in lymphocytes may help to reduce long-term sequelae from various forms of heart disease[6]. Of course, this is precisely what Livagen does and so there has been a great deal of research in this area[7], [8]. Changes to lymphocyte gene expression may help to reduce inflammation and the scarring that it leads to in individuals with HCM. Livagen may also be useful for preventing the onset of HCM in those who are genetically predisposed to the condition as well as following heart attack or other cardiac injury. Livagen may provide the basis for advanced preventative strategies that will reduce the overall morbidity and mortality associated with heart disease.

livagen과 고통

Enkephalins are short peptides that the body uses to signal pain. They bind to both mu and delta opioid receptors. Mu receptors, which bind morphine, cause a reduction in pain, blood pressure, and consciousness when activated. Delta receptor activation leads to reduced pain perception and may account for the respiratory depression seen with opiates. Work on bioregulatory peptides shows that Livagen inhibits the activity of enkephalin-degrading enzymes in the blood, thereby increasing levels of natural pain killers in the body[9]. Naturally, this suggests that Livagen may be an effective treatment for pain. There is ongoing research to determine how well it controls pain, what the side effects of enhanced enkephalin levels are, and whether there is any addictive potential as there is with opioids like Oxycontin.

Livagen과 Gi Tract

새로운 연구에 따르면 MY 및 델타 수용체는 활성화 될 때 GI Tract의 점막 장벽을 보호하는 데 중요한 역할을합니다. 이 환경에서 Livagen의 순 결과는 gi tract에 대한 vagal 신경 신호 전달 및 점막 산화 질소 및 프로스타글란딘의 수준을 변경하는 것입니다 [10]. 이것은 감염성 설사 치료에서부터 염증성 장 질환의 증상 및 장기 결과 감소에 이르기까지 모든에 유용 할 수있는 심오한 위 보호로 이어진다. 혈류에서 엔케팔린의 수준을 향상시킴으로써 이들 수용체의 활성화를 향상시키는 능력을 고려할 때, Livagen이 GI 관의 다양한 장애에 대한 잠재적 치료로 간주되고 있다는 것은 놀라운 일이 아닙니다.

livagen과 노화

지금까지 명백해야 할 것은 노화의 많은 영향이 DNA가 구성되는 방식의 변화와 따라서 접근하고 발현 될 수있는 유전자의 유형이라는 것입니다. Teimuraz Lezhava 교수는 노화의 염색질 변화에 관한 주요 당국의 이러한 변화에 대해 이러한 변화가 자세히 설명되어있다. 그의 작품은 크로모 좀 수차 수준이 나이가 들어감에 따라 증가한다는 것을 보여줍니다. 이러한 수차에는 염색질의 점진적인 축합 (DNA의 불 활성화 증가로 생각)과 수리 과정의 감소 (응축에서 발생하는 불 활성화에 이차적)가 포함됩니다 [11]. 축합 과정을 역전시키는 것은 실제로 수명을 연장하는 효과적인 수단 일 수 있음을 시사하는 좋은 증거가 있습니다. 결국, 침묵 유전자가 점차 더 빠른 노화로 이어지면, 이들 유전자를 재 활성화하면 과정이 느려질 것이다. Lezhavas 박사의 연구에 따르면 Livagen, Epitalon 및 소수의 다른 생물 조절 펩티드는 이미 DNA를 분해 함으로써이 과정에 영향을 미치는 것으로 알고 있습니다 [12]. 그의 연구는이 펩티드가 실제로 면역 조절 곤란 및 단백질 합성 감소와 관련하여 연령에 따라 발생하는 일부 기능 장애를 방해하는 데 도움이 될 수 있다고 믿을만한 충분한 이유가 있음을 보여줍니다.

Livagen 요약

Livagen is a short bioregulatory peptide that has direct effects on DNA structure and function. It is best known for its ability to decondense chromatin, thereby increasing the expression of certain genes and improving the “youthful” profile of cells. Its most studied effects are on lymphocytes of the immune system. Through these cells, Livagen helps to activate the immune system and offset disease in the heart, GI tract, immune system, and central nervous system. Livagen even shows promise in the area of nociception and pain control. Ongoing research will help to further unravel the promise of Livagen and bring humanity closer to understanding the processes of aging and senescence. Livagen exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. Livagen for sale at

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

블라디미르 카빈슨 is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the 러시아 및 우크라이나 의학 아카데미; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the 러시아 과학 아카데미; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of 펩티드 bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide Geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005). Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries. Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Livagen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between

1. “Chromatin,” Genome.gov. https://www.genome.gov/genetics-glossary/chromatin (2022 년 2 월 5 일 접근).
2. V. Kh. Khavinson et al., “Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People,” Bull. Exp. Biol. Med., vol. 134, 아니요. 4, pp. 389–392, 2002 년 10 월, doi : 10.1023/a : 1021924702103.
3. T. Lezhava, J. Monaselidze, T. Kadotani, N. Dvalishvili, and T. Buadze, “Anti-aging peptide bioregulators induce reactivation of chromatin,” Georgian Med. News, 아니요. 133, pp. 111–115, 2006 년 4 월.
4. “Lymphocyte,” Genome.gov. https://www.genome.gov/genetics-glossary/lymphocyte (2022 년 2 월 5 일 액세스).
5. T. A. Dzhokhadze, T. Z. Buadze, M. N. Gaiozishvili, N. G. Kakauridze, and T. A. Lezhava, “[Genomic instability in atherosclerosis],” Georgian Med. News, 닫다. 236, pp. 82-86, 2014 년 11 월.
6. T. Lezhava and T. Jokhadze, “Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals,” Ann. N. Y. Acad. Sci., vol. 1100, pp. 387–399, 2007 년 4 월, doi : 10.1196/annals.1395.043.
7. “[Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives],” Georgian Med. News, 아니요. 234, pp. 134–137, 2014 년 9 월.
8. T. A. Dzhokhadze, T. Z. Buadze, M. N. Gaĭozishvili, M. A. Rogava, and T. A. Lazhava, “[Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)],” Georgian Med. News, 아니요. 225, pp. 94–97, 2013 년 12 월.
9. N. V. Kost, O. I. Sokolov, M. V. Gabaeva, I. A. Zolotarev, V. V. Malinin, and V. K. Khavinson, “[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum],” Izv. Akad. Nauk. Ser. Biol., no. 4, pp. 427–429, Aug. 2003.
10. K. Gyires and A. Z. Rónai, “Supraspinal delta- and mu-opioid receptors mediate gastric mucosal protection in the rat,” J. Pharmacol. Exp. Ther., vol. 297, 아니오. 3, pp. 1010–1015, 2001 년 6 월.
11. T. A. Lezhava, “[Human chromosome functional characteristics and aging],” Adv. Gerontol. Uspekhi Gerontol., vol. 8, pp. 34–43, 2001.
12. V. K. Khavinson et al., “Peptide Epitalon activates chromatin at the old age,” Neuro Endocrinol. Lett., vol. 24, 아니오. 5, pp. 329–333, 2003 년 10 월.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. 이 웹 사이트에서 제공되는 제품은 투명한 연구를 위해 제공됩니다. 내역 연구 (라틴어 : 유리)는 신체 외부에서 수행됩니다. 이 제품은 의약품이나 약물이 아니며 FDA에 의해 의학적 상태, 질병 또는 질병을 예방, 치료 또는 치료하기 위해 승인되지 않았습니다. 인간이나 동물에 어떤 종류의 신체적으로 소개되는 것은 법에 의해 엄격히 금지되어 있습니다.